BTIG Raises Price Target for Liquidia (LQDA), Keeps Buy Rating

Liquidia Corporation (NASDAQ:LQDA) is one of the 10 Hot Mid Cap Stocks to Buy Now. On August 13, BTIG increased its price target for Liquidia Corporation (NASDAQ:LQDA) from $40 to $49 and kept a Buy rating.

BTIG noted that Liquidia Corporation (NASDAQ:LQDA) has seen stronger-than-expected adoption of YUTREPIA. As of August 8, 900 unique patient prescriptions were written, which led to over 550 patient starts. This performance surpassed BTIG’s earlier expectations for patient numbers that weren’t expected until late 2025 or early 2026.

The research firm increased its revenue estimates for YUTREPIA significantly. BTIG now expects Liquidia Corporation (NASDAQ:LQDA) to report $76.4 million in YUTREPIA revenue for 2025, up from $26.5 million. For 2026, the firm raised its forecast to $601.9 million, up from $215.9 million.

BTIG expects 50 new patients will start using YUTREPIA each week through the end of 2025. The firm expects the annualized net price per patient to be $225,000.

Liquidia Corporation (NASDAQ:LQDA) is a biopharmaceutical company that develops and commercializes therapies for rare cardiopulmonary diseases.

While we acknowledge the potential of LQDA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Best Revenue Growth Stocks to Buy Now and 11 Best Under-the-Radar Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.